Adicet Bio (ACET)

Executive Summary

Adicet Bio is a clinical-stage biotechnology company developing off-the-shelf, allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Leveraging the unique MHC-independent tumor-homing and dual innate/adaptive immune functions of engineered gamma delta 1 T cells, the company aims to overcome key limitations of current autologous CAR-T therapies, such as manufacturing delays, high cost, and patient-specific variability. Adicet’s platform utilizes a healthy donor-derived, cryopreserved cell product that can be readily administered, providing the potential for scalable, accessible, and repeat dosing. The company is advancing a pipeline of candidates targeting hematologic malignancies and autoimmune disorders, with lead program ADI-001 in clinical development for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Adicet’s clinical progress includes early data from Phase 1 studies showing encouraging safety and efficacy signals for ADI-001 in NHL, with manageable cytokine release syndrome and no graft-versus-host disease observed. The company is also exploring ADI-001 in autoimmune indications such as lupus nephritis, capitalizing on the potential of gamma delta T cells to deplete pathogenic B cells. Additionally, preclinical programs like ADI-270 for acute myeloid leukemia (AML) are advancing. With a strong intellectual property position and a differentiated platform, Adicet Bio represents a compelling approach in the allogeneic cell therapy space. However, the company remains at an early clinical stage, and successful demonstration of durable efficacy and manufacturing consistency will be critical for future value creation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data update for ADI-001 in relapsed/refractory B-NHL80% success
• H1 2026IND filing for autoimmune indication (e.g., lupus nephritis)70% success
• Q4 2026Initial safety/efficacy data from Phase 1/2 trial of ADI-270 in AML60% success